Cooper Companies Inc (NYSE:COO) – Investment analysts at William Blair issued their Q1 2019 earnings estimates for shares of Cooper Companies in a report released on Saturday. William Blair analyst B. Weinstein expects that the medical device company will earn $2.91 per share for the quarter. William Blair also issued estimates for Cooper Companies’ Q2 2019 earnings at $3.14 EPS, Q3 2019 earnings at $3.38 EPS and Q4 2019 earnings at $3.47 EPS.
Cooper Companies (NYSE:COO) last announced its earnings results on Thursday, March 8th. The medical device company reported $2.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.51 by $0.28. Cooper Companies had a net margin of 7.83% and a return on equity of 16.90%. The business had revenue of $590.00 million during the quarter, compared to analysts’ expectations of $583.07 million. During the same quarter in the prior year, the company posted $1.93 earnings per share. The firm’s revenue was up 18.2% on a year-over-year basis.
Other research analysts have also recently issued research reports about the stock. Cleveland Research cut shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Friday, February 9th. BMO Capital Markets restated an “outperform” rating and set a $280.00 target price (up previously from $277.00) on shares of Cooper Companies in a report on Friday, March 9th. TheStreet cut shares of Cooper Companies from a “b” rating to a “c” rating in a report on Thursday, March 8th. Oppenheimer set a $250.00 target price on shares of Cooper Companies and gave the stock a “hold” rating in a report on Friday, December 8th. Finally, Jefferies Group restated a “buy” rating and set a $285.00 target price on shares of Cooper Companies in a report on Friday, March 9th. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Cooper Companies presently has a consensus rating of “Hold” and an average price target of $267.50.
Shares of Cooper Companies (NYSE COO) traded down $0.89 on Tuesday, reaching $231.96. 83,931 shares of the company traded hands, compared to its average volume of 490,759. Cooper Companies has a fifty-two week low of $194.29 and a fifty-two week high of $260.26. The firm has a market capitalization of $11,553.85, a PE ratio of 66.72, a price-to-earnings-growth ratio of 1.85 and a beta of 0.61. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.83 and a quick ratio of 1.61.
A number of hedge funds and other institutional investors have recently bought and sold shares of COO. Crossmark Global Holdings Inc. bought a new stake in Cooper Companies during the third quarter worth $339,000. Canada Pension Plan Investment Board bought a new stake in Cooper Companies during the third quarter worth $163,000. Prudential Financial Inc. raised its position in Cooper Companies by 1.8% during the third quarter. Prudential Financial Inc. now owns 69,808 shares of the medical device company’s stock worth $16,552,000 after acquiring an additional 1,240 shares in the last quarter. New York State Common Retirement Fund raised its position in Cooper Companies by 0.5% during the third quarter. New York State Common Retirement Fund now owns 226,107 shares of the medical device company’s stock worth $53,612,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Toronto Dominion Bank raised its position in shares of Cooper Companies by 12.0% in the third quarter. Toronto Dominion Bank now owns 18,536 shares of the medical device company’s stock valued at $4,395,000 after purchasing an additional 1,984 shares during the period. 98.53% of the stock is currently owned by hedge funds and other institutional investors.
In other Cooper Companies news, Director Stanley Md Zinberg sold 5,000 shares of the company’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $224.66, for a total transaction of $1,123,300.00. Following the sale, the director now directly owns 6,090 shares of the company’s stock, valued at $1,368,179.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Allan E. Rubenstein sold 500 shares of the company’s stock in a transaction on Wednesday, December 27th. The stock was sold at an average price of $222.00, for a total transaction of $111,000.00. Following the sale, the director now directly owns 6,590 shares in the company, valued at $1,462,980. The disclosure for this sale can be found here. Insiders have sold 62,081 shares of company stock worth $14,879,687 over the last ninety days. Insiders own 1.60% of the company’s stock.
Cooper Companies Company Profile
The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.